Samsung Pharmaceutical

At a glance

Samsung Pharmaceutical filed 27 disclosures in the last 12 months, including 3 5% holder and 1 issuance. The most recent key filing was on Sep 2.

Revenue for 2025 was ₩46.1B, up 4% on 2024. It made an operating loss of ₩18.1B. Debt was 38% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩18.9B and operating loss of ₩7B.

The 2025 annual report lists 87 employees with an average tenure of 6.3 years and average pay of ₩66.1M, #721 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩99M each on average. It paid no cash dividend for 2025. (주)젬백스앤카엘 and related parties held 10.47% at year end.

From the 2025 annual report

Staff: 87 (50 men, 37 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩5.8B. Directors and auditors: 7, paid ₩690M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)젬백스앤카엘 holds 10.46%; with 2 related parties the group holds 10.47% of common shares at year end.

Auditor: 삼덕회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary